Shanghai – September 08, 2026 -- Mabwell (688062.SH, 02493.HK) reported that its anti-ST2 monoclonal antibody 9MW1911 reduced the annualized rate of severe COPD exacerbations by 100% in the 900 mg dose group compared with placebo, according to Phase Ib/IIa data presented as a poster at the European Respiratory Society International Congress 2026 (ERS 2026).